Every article, report, and earnings note where DHR appears.
6 articles
Danaher Corporation (DHR) rises after investors step back in following a sharp post-earnings selloff. The company beat quarterly EPS estimates but trimmed full-year revenue growth guidance, sparking a rebound as traders viewed the weakness as timing-related rather than a broken business.
Danaher is seeing better operating momentum across Life Sciences, Diagnostics, and Biotechnology, but the stock still trades at a premium that limits upside. The report keeps a Buy rating with fair value set at $225.
Danaher Corporation (DHR) falls sharply after earnings as investors focus on weaker-than-expected forward guidance rather than the quarter’s beat on revenue and EPS. The selloff reflects a valuation reset for a premium stock priced for stronger growth.
Cue Health Inc. (NASDAQ: HLTH) is expected to list on 2026-07-21 in a priced deal with a $15 to $17 range. The company is pitching connected diagnostics and at-home testing, but shareholders should watch how much of the story still depends on testing demand and regulatory execution.
These seven healthcare stocks combine recurring demand, identifiable franchises, and varying mixes of scale, profitability, and growth heading into June 2026.
Danaher Corporation (DHR) fell 5.4% after its latest earnings report, even with an EPS beat and a modest guidance raise. Investors focused on soft revenue, weak core growth, and mixed segment performance, especially in Diagnostics, which outweighed the company’s strong margins and cash flow.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate DHR Report